









Markets
/
Stocks
/
nasdaq-atyr
/

aTyr Pharma Inc

ATYR

0.827USD

-0.054-6.14%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

76.77MMarket Cap

LossP/E TTM



aTyr Pharma Inc

0.827

-0.054-6.14%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of aTyr Pharma Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

aTyr Pharma Inc's Score

Industry at a Glance

Industry Ranking

170 / 407

Overall Ranking

307 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Hold

Current Rating

10.111

Target Price

+1067.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

aTyr Pharma Inc Highlights

StrengthsRisks

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Growing

The company is in a growing phase, with the latest annual income totaling USD 235.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 235.00K.

Overvalued

The company’s latest PE is -1.11, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.66M shares, decreasing 5.59% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 518.36K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.87.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.15, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.15

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.36

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

aTyr Pharma Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.36, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -1.11, which is -21.60% below the recent high of -0.87 and -650.57% above the recent low of -8.34.

Score

Industry at a Glance

Previous score

7.36

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 170/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 6.91, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for aTyr Pharma Inc is 3.50, with a high of 35.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

6.91

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Hold

Current Rating

10.111

Target Price

+1048.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

aTyr Pharma Inc

ATYR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.59, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.07 and the support level at 0.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.52

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.161

Neutral

RSI(14)

29.161

Sell

STOCH(KDJ)(9,3,3)

9.964

Oversold

ATR(14)

0.066

Low Volatility

CCI(14)

-166.080

Sell

Williams %R

96.779

Oversold

TRIX(12,20)

-2.320

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.886

Sell

MA10

0.927

Sell

MA20

0.969

Sell

MA50

2.108

Sell

MA100

3.702

Sell

MA200

3.677

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 64.97%, representing a quarter-over-quarter decrease of 13.07%. The largest institutional shareholder is The Vanguard, holding a total of 4.66M shares, representing 4.75% of shares outstanding, with 10.62% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

13.35M

+3.55%

Federated Hermes Global Investment Management Corp.

14.67M

BlackRock Institutional Trust Company, N.A.

5.34M

+253.28%

The Vanguard Group, Inc.

Star Investors

4.66M

+16.18%

Octagon Capital Advisors LP

3.82M

+7.55%

Tikvah Management LLC

2.46M

Geode Capital Management, L.L.C.

2.10M

+126.13%

UBS Financial Services, Inc.

1.75M

+8.60%

Woodline Partners LP

1.68M

Millennium Management LLC

1.60M

+0.07%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 1.52, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.